DalsnaFinance › Analyst accuracy › Bank of America › MRNA target
BofA upgrades Moderna stock rating on cancer drug progress
BofA Securities upgraded Moderna (NASDAQ:MRNA) to Neutral from Underperform on Tuesday and raised its price target to $170 from $40.
A fact about what Bank of America published, as reported by Investing.com, not a recommendation from Dalsna Finance; Bank of America is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.